Abstract

Human cytomegalovirus (HCMV) is a highly prevalent herpes virus which persists as a latent infection and has been detected in several different tumor types. HCMV disease is rare but may occur in high-risk settings, often manifesting as a pulmonary infection. To date HCMV has not been investigated in malignant pleural mesothelioma (MPM). In a consecutive case series of 144 MPM patients we evaluated two biomarkers of HCMV: IgG serostatus (defined as positive and negative) and DNAemia (>100 copies/mL of cell free HCMV DNA in serum). Approximately half of the MPM patient population was HCMV IgG seropositive (51%). HCMV DNAemia was highly prevalent (79%) in MPM and independent of IgG serostatus. DNAemia levels consistent with high level current infection (>1000 copies/mL serum) were present in 41% of patients. Neither IgG serostatus nor DNAemia were associated with patient survival. In tissues, we observed that HCMV DNA was present in 48% of tumors (n = 40) and only 29% of normal pleural tissue obtained from individuals without malignancy (n = 21). Our results suggest nearly half of MPM patients have a high level current HCMV infection at the time of treatment and that pleural tissue may be a reservoir for latent HCMV infection. These findings warrant further investigation to determine the full spectrum of pulmonary infections in MPM patients, and whether treatment for high level current HCMV infection may improve patient outcomes.

Highlights

  • Malignant Pleural Mesothelioma (MPM) is a rare cancer that develops in the protective lining around the lungs and is tightly linked to asbestos exposure [1]

  • Human cytomegalovirus (HCMV) IgG seroprevalence was 52%, and serostatus was not associated with the presence nor level of HCMV DNAemia

  • Age, sex, histology, and asbestos exposure were similar across HCMV DNAemia groups

Read more

Summary

Introduction

Malignant Pleural Mesothelioma (MPM) is a rare cancer that develops in the protective lining around the lungs and is tightly linked to asbestos exposure [1]. The prognosis is very poor, with a 5-year survival rate of 9% [1, 2]. The Masonic Cancer Center supported the study through a grant given to HN (R35 00052643). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.